1. Home
  2. QNC vs RLMD Comparison

QNC vs RLMD Comparison

Compare QNC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QNC

Quantum eMotion Corp. Common Shares

N/A

Current Price

$1.96

Market Cap

434.7M

Sector

N/A

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$4.43

Market Cap

461.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QNC
RLMD
Founded
2007
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.7M
461.9M
IPO Year
2026
2012

Fundamental Metrics

Financial Performance
Metric
QNC
RLMD
Price
$1.96
$4.43
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.40
AVG Volume (30 Days)
415.4K
1.0M
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$1.90
$1.13
52 Week High
$3.59
$8.00

Technical Indicators

Market Signals
Indicator
QNC
RLMD
Relative Strength Index (RSI) 31.99 37.97
Support Level N/A $4.29
Resistance Level $2.60 $4.55
Average True Range (ATR) 0.10 0.17
MACD -0.01 0.02
Stochastic Oscillator 3.97 35.25

Price Performance

Historical Comparison
QNC
RLMD

About QNC Quantum eMotion Corp. Common Shares

Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: